At the virtual Great Debates & Updates in Hematologic Malignancies, Jonathan Kaufman, MD, discussed the standard front-line approach for treating patients with MM ineligible for transplantation.
Joseph Mikhael, MD, talks about what attendees can expect from the myeloma session at this year's virtual Great Debates & Updates in Hematologic Malignancies.
Agner Paner, MD, will address updates in supportive care for patients with multiple myeloma at the virtual 2020 Great Debates & Updates in Hematologic Malignancies.
Thomas G. Martin, MD, discusses MRD assessment in patients with multiple myeloma and how it may be able to influence therapy selection for these patients.
Thomas G. Martin, MD, discusses promising immunotherapies in the pipeline for multiple myeloma and how they will affect the future treatment of this disease.
Andrew J. Cowan, MD, explains when physicians should consider a second autologous stem cell transplant for patients with relapsed multiple myeloma.
Joseph Mikhael, MD, MEd, FRCPC, discussed novel small molecule inhibitors in multiple myeloma.
Suzanne Lentzsch, MD, PhD, presented data that three drug regimens should be considered standard for myeloma salvage therapy.